Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
Journal
ESMO open
Journal Volume
7
Journal Issue
1
Date Issued
2022-02
Author(s)
Cao, Y
Qin, S
Luo, S
Li, Z
Cheng, Y
Fan, Y
Sun, Y
Yin, X
Yuan, X
Li, W
Liu, T
Lin, X
Kim, S-B
Kojima, T
Zhang, J
Lee, S-H
Bai, Y
Muro, K
Doi, T
Bai, C
Gu, K
Pan, H-M
Bai, L
Yang, J-W
Cui, Y
Lu, W
Chen, J
Abstract
In the randomized phase III KEYNOTE-181 study, pembrolizumab prolonged overall survival (OS) compared with chemotherapy as second-line therapy in patients with advanced esophageal cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10. We report a post hoc subgroup analysis of patients with esophageal squamous cell carcinoma (ESCC) enrolled in KEYNOTE-181 in Asia, including patients from the KEYNOTE-181 China extension study.
Subjects
PD-1; PD-L1 CPS; esophageal squamous cell carcinoma; pembrolizumab
SDGs
Type
journal article